Zevenbergen Capital Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Zevenbergen Capital Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-180,828	Closed	-$21.9M	–	83
2017 Q1	$21.9M	Sell	180,828 -221,532	-55%	-$28.6M	1.01%	35
2016 Q4	$49.2M	Sell	402,360 -17,935	-4%	-$2.19M	2.32%	18
2016 Q3	$51.5M	Buy	420,295 +75,060	+22%	+$9.66M	2.12%	17
2016 Q2	$40.3M	Sell	345,235 -4,445	-1%	-$631K	1.89%	21
2016 Q1	$48.7M	Sell	349,680 -1,020	-0.3%	-$150K	2.2%	18
2015 Q4	$66.9M	Buy	350,700 +55,305	+19%	+$9.66M	2.72%	14
2015 Q3	$46.2M	Sell	295,395 -2,265	-0.8%	-$413K	1.98%	24
2015 Q2	$53.8M	Buy	297,660 +36,537	+14%	+$6.31M	2.09%	23
2015 Q1	$45.3M	Buy	261,123 +247,091	+1,761%	+$44.7M	1.89%	27
2014 Q4	$2.6M	Buy	+14,032	New	+$2.6M	0.11%	43

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Zevenbergen Capital Investments's ALXN Position: Q2 2017 in Review

Zevenbergen Capital Investments sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 180,828 shares — an estimated $21.9M sold.

Zevenbergen Capital Investments first reported a position in ALXN in Q4 2014 and held it in 10 quarters. The position peaked at $66.9M in Q4 2015. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Zevenbergen Capital Investments reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Zevenbergen Capital Investments sold 180,828 Alexion Pharmaceuticals shares in Q2 2017, an estimated $21.9M.
Zevenbergen Capital Investments first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Zevenbergen Capital Investments's Alexion Pharmaceuticals position peaked at $66.9M in Q4 2015.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Zevenbergen Capital Investments's 13F filing for Q2 2017, filed 11 Aug 2017.